Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease

Human Gene Therapy

Volumn 24, Issue 11, 2013, Pages 948-963

  Kaminsky, Stephen M ^a   Rosengart, Todd K ^b   Rosenberg, Jonathan ^a   Chiuchiolo, Maria J ^a   Van De Graaf, Benjamin ^a   Sondhi, Dolan ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN 1; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; PLASMID VECTOR; PROTEIN BCL 2; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VIRUS VECTOR;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; CARDIAC GENE THERAPY; CATHETER; CELL SPECIFICITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENDOTHELIUM CELL; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INJECTION; INTRACORNEAL DRUG ADMINISTRATION; MESENCHYMAL STEM CELL; MULTIGENE FAMILY; NONHUMAN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CORONARY VESSELS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMIDS;

EID: 84886791503     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.2516     Document Type: Review

References (121)

1. Ahmed, R.P., Haider, K.H., Shujia, J., et al. (2010). Sonic Hedgehog gene delivery to the rodent heart promotes angio-genesis via iNOS/netrin-1/PKC pathway. PLoS One 5, e8576.
2. Ailawadi, M., Lee, J.M., Lee, S., et al. (2002). Adenovirus vector-mediated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing. Surgery 131, 219-227. (Pubitemid 34169553)
3. Amano, H., Hackett, N.R., Kaner, R.J., et al. (2005). Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol. Ther. 12, 716-724. (Pubitemid 41350153)
4. Aoki, M., Morishita, R., Taniyama, Y., et al. (2000). Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther. 7, 417-427. (Pubitemid 30156554)
5. Azarnoush, K., Maurel, A., Sebbah, L., et al. (2005). Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. J. Thorac. Cardiovasc. Surg. 130, 173-179. (Pubitemid 40941687)
6. Beenken, A., and Mohammadi, M. (2009). The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235-253.
7. Brindle, N.P., Saharinen, P., and Alitalo, K. (2006). Signaling and functions of angiopoietin-1 in vascular protection. Circ. Res. 98, 1014-1023.
8. Bruce, R.A., Kusumi, F., and Hosmer, D. (1973). Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am. Heart J. 85, 546-562.
9. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-660. (Pubitemid 36749213)
10. Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307.
11. Chae, J.K., Kim, I., Lim, S.T., et al. (2000). Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler. Thromb. Vasc. Biol. 20, 2573-2578.
12. Crystal, R.G., Harvey, B.G., Wisnivesky, J.P., et al. (2002). Analysis of risk factors for local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13, 65-100. (Pubitemid 34075173)
13. Crystal, R.G., Kaminsky, S.M., Hackett, N.R., et al. (2012). Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery. Hum. Gene Ther. 23, 438-441.
14. Elmadbouh, I., Haider, H.K., Jiang, S., et al. (2007). Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J. Mol. Cell Cardiol. 42, 792-803. (Pubitemid 46527603)
15. Emanueli, C., and Madeddu, P. (2001). Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. Br. J. Pharmacol. 133, 951-958. (Pubitemid 32762403)
16. Favaloro, L., Diez, M., Mendiz, O., et al. (2012). High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial. Catheter. Cardiovasc. Interv. [Epub ahead of print] DOI: 10.1002/ccd.24555
17. Ferrara, N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611. (Pubitemid 39099316)
18. Ferrara, N., Gerber, H.P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676. (Pubitemid 36749215)
19. Flamme, I., Frolich, T., and Risau, W. (1997). Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell Physiol. 173, 206-210. (Pubitemid 27481131)
20. Fortuin, F.D., Vale, P., Losordo, D.W., et al. (2003). One-year follow-up of direct myocardial gene transfer of vascular en-dothelial growth factor-2 using naked plasmid deoxyr-ibonucleic acid by way of thoracotomy in no-option patients. Am. J. Cardiol. 92, 436-439. (Pubitemid 36959880)
21. French, B.A., Mazur, W., Geske, R.S., et al. (1994). Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 90, 2414-2424.
22. Funatsu, T., Sawa, Y., Ohtake, S., et al. (2002). Therapeutic an-giogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J. Thorac. Cardiovasc. Surg. 124, 1099-1105. (Pubitemid 35416995)
23. Giacca, M., and Zacchigna, S. (2012). VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 19, 622-629.
24. Gibbons, R.J., Balady, G.J., Bricker, J.T., et al. (2002). ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J. Am. Coll. Cardiol. 40, 1531-1540. (Pubitemid 35192881)
25. Giordano, F.J., Ping, P., McKirnan, M.D., et al. (1996). In-tracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2, 534-539. (Pubitemid 26151517)
26. Grines, C.L., Watkins, M.W., Helmer, G., et al. (2002). Angio-genic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105, 1291-1297. (Pubitemid 34260418)
27. Grines, C.L., Watkins, M.W., Mahmarian, J.J., et al. (2003). A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42, 1339-1347. (Pubitemid 37267270)
28. Guzman, R.J., Lemarchand, P., Crystal, R.G., et al. (1993). Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ. Res. 73, 1202-1207. (Pubitemid 23340215)
29. Gyongyosi, M., Khorsand, A., Zamini, S., et al. (2005). NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EURO-INJECT-ONE multicenter double-blind randomized study. Circulation 112, I157-I165. (Pubitemid 41266668)
30. Haider, H.K., Ye, L., Jiang, S., et al. (2004). Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J. Mol. Med (Berl.) 82, 539-549. (Pubitemid 39149863)
31. Hao, X., Mansson-Broberg, A., Grinnemo, K.H., et al. (2007). Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Car-diovasc. Res. 73, 481-487. (Pubitemid 46084927)
32. Harvey, B.G., Maroni, J., O'Donoghue, K.A., et al. (2002). Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15-63. (Pubitemid 34075172)
33. Hattan, N., Warltier, D., Gu, W., et al. (2004). Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth. Am. J. Physiol. Heart Circ. Physiol. 287, H488-H493. (Pubitemid 38955276)
34. Hayakawa, H., and Shibasaki, F. (2013). Regulation of angio-genesis of hypoxia-inducible factors. In Biochemical Basis and Therapeutic Implications of Angiogenesis. J.L. Mehta and N.S. Dhalla, eds. (Springer, New York, NY), pp. 93-106.
35. Hedman, M., Hartikainen, J., Syvanne, M., et al. (2003). Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107, 2677-2683. (Pubitemid 36667240)
36. Hedman, M., Muona, K., Hedman, A., et al. (2009). Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 16, 629-634.
37. Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. (2011). Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123, 933-944.
38. Heinl-Green, A., Radke, P.W., Munkonge, F.M., et al. (2005). The efficacy of a "master switch gene" HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur. Heart J. 26, 1327-1332. (Pubitemid 41435465)
39. Helisch, A., and Schaper, W. (2003). Arteriogenesis: the development and growth of collateral arteries. Microcirculation 10, 83-97. (Pubitemid 39004238)
40. Hendel, R.C., Berman, D.S., Di Carli, M.F., et al. (2009). ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation 119, e561-e587.
41. Henry, T.D., and Satran, D. (2012). Therapeutic angiogenesis. In Coronary Artery Disease. G.W. Barsness and D.R. Holmes, eds. (Springer-Verlag Ltd., London), pp. 67-74.
42. Henry, T.D., Grines, C.L., Watkins, M.W., et al. (2007). Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50, 1038-1046. (Pubitemid 47354223)
43. Hinkel, R., Lebherz, C., Fydanaki, M., et al. (2013). Angiogenetic potential of Ad2/Hif-1alpha/VP16 after regional application in a preclinical pig model of chronic ischemia. Curr. Vasc. Pharmacol. 11, 29-37.
44. Hlatky, M.A., Boothroyd, D.B., Bravata, D.M., et al. (2009). Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373, 1190-1197.
45. Hofmann, A., Nolan, G.P., and Blau, H.M. (1996). Rapid retro-viral delivery of tetracycline-inducible genes in a single auto-regulatory cassette. Proc. Natl. Acad. Sci. USA 93, 5185-5190. (Pubitemid 26159423)
46. Huang, L., and Viroonchatapan, E. (1999). Introduction. In Nonviral Vectors for Gene Therapy. L. Huang, M.-C. Hung, and E. Wagner, eds. (Academic Press, San Diego, CA), pp. 3-24.
47. Hundley, W.G., Hamilton, C.A., Thomas, M.S., et al. (1999). Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation 100, 1697-1702. (Pubitemid 29485251)
48. Iervolino, A., Trisciuoglio, D., Ribatti, D., et al. (2002). Bcl-2 overexpression in human melanoma cells increases angio-genesis through VEGF mRNA stabilization and HIF-1-medi-ated transcriptional activity. FASEB J. 16, 1453-1455.
49. Iwakura, A., Fujita, M., Ikemoto, M., et al. (2000). Myocardial ischemia enhances the expression of acidic fibroblast growth factor in human pericardial fluid. Heart Vessels 15, 112-116. (Pubitemid 32236950)
50. Jiang, S., Haider, H.K., Idris, N.M., et al. (2006). Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angio-myogenesis for cardiac repair. Circ. Res. 99, 776-784. (Pubitemid 44498311)
51. Jolicoeur, E.M., Cartier, R., Henry, T.D., et al. (2012). Patients with coronary artery disease unsuitable for revascularization: definition, general principles, and a classification. Can. J. Cardiol. 28, S50-S59.
52. Kaminsky, S.M., Quach, L., Chen, S., et al. (2013). Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum. Gene Ther. Clin. Dev. 24, 38-46.
53. Kapur, N.K., and Rade, J.J. (2008). Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease. Trends Car-diovasc. Med. 18, 133-141. (Pubitemid 351794542)
54. Kaski, J.C., and Consuegra-Sanchez, L. (2013). Evaluation of ASPIRE trial: a phase III pivotal registration trial, using in-tracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert. Opin Biol Ther. [Epub ahead of print] DOI: 10.1517/14712598.2013.827656
55. Kastrup, J., Jorgensen, E., Ruck, A., et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pec-toris: a randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 45, 982-988. (Pubitemid 40432426)
56. Kastrup, J., Jorgensen, E., Fuchs, S., et al. (2011). A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 6, 813-818.
57. Kilian, E.G., Sadoni, S., Vicol, C., et al. (2010). Myocardial transfection of hypoxia inducible factor-1alpha via an adeno-viral vector during coronary artery bypass grafting: a multi-center phase I and safety study. Circ. J. 74, 916-924.
58. Klein, L., and Greenland, P. (2007). Other risk factors for coronary artery disease. In Textbook of Cardiovascular Medicine. E. Topol, ed. (Lippincott Williams & Wilkins, Philadelphia, PA), pp. 141-174.
59. Kondo, I., Ohmori, K., Oshita, A., et al. (2004). Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction. J. Am. Coll. Cardiol. 44, 644-653. (Pubitemid 39078194)
60. Kukula, K., Chojnowska, L., Dabrowski, M., et al. (2011). In-tramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am. Heart. J. 161, 581-589.
61. Lahteenvuo, J.E., Lahteenvuo, M.T., Kivela, A., et al. (2009). Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 119, 845-856.
62. Lavu, M., Gundewar, S., and Lefer, D.J. (2011). Gene therapy for ischemic heart disease. J. Mol. Cell Cardiol. 50, 742-750.
63. Lee, R.J., Springer, M.L., Blanco-Bose, W.E., et al. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102, 898-901.
64. Leotta, E., Patejunas, G., Murphy, G., et al. (2002). Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J. Thorac. Car-diovasc. Surg. 123, 1101-1113.
65. Li, W., Ma, N., Ong, L.L., et al. (2007). Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25, 2118-2127. (Pubitemid 47258191)
66. Losordo, D.W., Vale, P.R., Hendel, R.C., et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105, 2012-2018. (Pubitemid 34465261)
67. Macgovern, C.J., Mack, C.A., Budenbender, K.T., et al. (1996). Gene transfer utilizing a replication-deficient adenovirus vector expressing vascular endothelial growth factor protects against acute arterial occlusion in the setting of chronic ischemia. Circulation 94, I-636-I-637.
68. Mack, C.A., Magovern, C.J., Budenbender, K.T., et al. (1998). Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J. Vasc. Surg. 27, 699-709. (Pubitemid 28201761)
69. Marcassa, C., Bax, J.J., Bengel, F., et al. (2008). Clinical value, cost-effectiveness, and safety of myocardial perfusion scin-tigraphy: a position statement. Eur. Heart J. 29, 557-563. (Pubitemid 351264184)
70. Markkanen, J.E., Rissanen, T.T., Kivela, A., et al. (2005). Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovasc. Res. 65, 656-664. (Pubitemid 40138986)
71. Matsumoto, R., Omura, T., Yoshiyama, M., et al. (2005). Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 25, 1168-1173. (Pubitemid 40776604)
72. Medical News Today (2006). Corautus Genetics Announces Final Efficacy Results Of GENASIS Phase IIb Clinical Trial. www.medicalnewstoday.com/releases/ 53786.php (accessed September 2013).
73. Miyagawa, S., Sawa, Y., Taketani, S., et al. (2002). Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 105, 2556-2561. (Pubitemid 34568980)
74. Muhlhauser, J., Jones, M., Yamada, I., et al. (1996). Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther. 3, 145-153. (Pubitemid 26117424)
75. Nabel, E.G., and Braunwald, E. (2012). A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54-63.
76. Ninomiya, M., Koyama, H., Miyata, T., et al. (2003). Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model. Gene Ther. 10, 1152-1160. (Pubitemid 36896590)
77. Okin, P.M., and Kligfield, P. (1995). Heart rate adjustment of ST segment depression and performance of the exercise electrocardiogram: a critical evaluation. J. Am. Coll. Cardiol. 25, 1726-1735.
78. Park, J.E., Keller, G.A., and Ferrara, N. (1993). The vascular en-dothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317-1326. (Pubitemid 24045761)
79. Patel, S.R., Lee, L.Y., Mack, C.A., et al. (1999). Safety of direct myo-cardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum. Gene Ther. 10, 1331-1348. (Pubitemid 29267588)
80. Patil, A.S., Sable, R.B., and Kothari, R.M. (2012). Occurrence, biochemical profile of vascular endothelial growth factor (VEGF) isoforms and their functions in endochondral ossification. J. Cell Physiol. 227, 1298-1308.
81. Patila, T., Ikonen, T., Rutanen, J., et al. (2006). Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia. J. Heart Lung Transplant. 25, 206-213. (Pubitemid 43156373)
82. Pellikka, P.A., Nagueh, S.F., Elhendy, A.A., et al. (2007). American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J. Am. Soc. Echocardiogr. 20, 1021-1041. (Pubitemid 47321932)
83. Post, M.J., Sato, K., Murakami, M., et al. (2006). Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R494-R500.
84. Reilly, J.P., Grise, M.A., Fortuin, F.D., et al. (2005). Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J. Interv. Car-diol. 18, 27-31. (Pubitemid 40468771)
85. Retuerto, M.A., Schalch, P., Patejunas, G., et al. (2004). Angio-genic pretreatment improves the efficacy of cellular cardio-myoplasty performed with fetal cardiomyocyte implantation. J. Thorac. Cardiovasc. Surg. 127, 1041-1049.
86. Ripa, R.S., Wang, Y., Jorgensen, E., et al. (2006). Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 27, 1785-1792. (Pubitemid 44297382)
87. Rischpler, C., Nekolla, S., and Schwaiger, M. (2013). PET and SPECT in heart failure. Curr. Cardiol. Rep. 15, 337.
88. Rosengart, T.K., DeBois, W., O'Hara, M., et al. (1998). Retrograde autologous priming for cardiopulmonary bypass: a safe and effective means of decreasing hemodilution and transfusion requirements. J. Thorac. Cardiovasc. Surg. 115, 426-438.
89. Rosengart, T.K., Lee, L.Y., Patel, S.R., et al. (1999). Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468-474. (Pubitemid 29360154)
90. Rosengart, T.K., Fallon, E., and Crystal, R.G. (2012). Cardiac biointerventions: whatever happened to stem cell and gene therapy? Innovations (Phila) 7, 173-179.
91. Roy, H., Bhardwaj, S., and Yla-Herttuala, S. (2006). Biology of vascular endothelial growth factors. FEBS Lett. 580, 2879-2887. (Pubitemid 43729175)
92. Ruixing, Y., Jiaquan, L., Jie, C., et al. (2006). Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis. Growth Factors 24, 209-217. (Pubitemid 44679290)
93. Rutanen, J., Rissanen, T.T., Markkanen, J.E., et al. (2004). Ade-noviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109, 1029-1035. (Pubitemid 38282857)
94. Sala, V., and Crepaldi, T. (2011). Novel therapy for myocardial infarction: can HGF/Met be beneficial? Cell Mol. Life Sci. 68, 1703-1717.
95. Salcedo, R., Wasserman, K., Young, H.A., et al. (1999). Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am. J. Pathol. 154, 1125-1135. (Pubitemid 29169747)
96. Sarkar, N., Ruck, A., Kallner, G., et al. (2001). Effects of in-tramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy. J. Intern. Med. 250, 373-381. (Pubitemid 32990045)
97. Schalch, P., Patejunas, G., Retuerto, M., et al. (2004a). Homozygous deletion of early growth response 1 gene and critical limb ischemia after vascular ligation in mice: evidence for a central role in vascular homeostasis. J. Thorac. Cardiovasc. Surg. 128, 595-601. (Pubitemid 39278394)
98. Schalch, P., Rahman, G.F., Patejunas, G., et al. (2004b). Adeno-viral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state. J. Thorac. Cardiovasc. Surg. 127, 535-540. (Pubitemid 38176660)
99. Shyu, K.G., Manor, O., Magner, M., et al. (1998). Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98, 2081-2087. (Pubitemid 28512235)
100. Siddiqui, A.J., Blomberg, P., Wardell, E., et al. (2003). Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem. Biophys. Res. Commun. 310, 1002-1009. (Pubitemid 37188722)
101. Stewart, D.J., Hilton, J.D., Arnold, J.M., et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of Ad-VEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 13, 1503-1511. (Pubitemid 44574158)
102. Stewart, D.J., Kutryk, M.J., Fitchett, D., et al. (2009). VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther. 17, 1109-1115.
103. Stiermaier, T., Schuler, G., Boudriot, E., et al. (2013). Is percutaneous coronary intervention as effective as bypass surgery in left main stem coronary artery stenosis? Herz 38, 147-152.
104. Suri, C., McClain, J., Thurston, G., et al. (1998). Increased vas-cularization in mice overexpressing angiopoietin-1. Science 282, 468-471. (Pubitemid 28483672)
105. Symes, J.F., Losordo, D.W., Vale, P.R., et al. (1999). Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68, 830-836.
106. Takeshita, S., Weir, L., Chen, D., et al. (1996). Therapeutic an-giogenesis following arterial gene transfer of vascular endo-thelial growth factor in a rabbit model of hindlimb ischemia. Biochem. Biophys. Res. Commun. 227, 628-635. (Pubitemid 26362853)
107. Taniyama, Y., Morishita, R., Aoki, M., et al. (2001). Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 8, 181-189. (Pubitemid 32186129)
108. Thomas, C.E., Ehrhardt, A., and Kay, M.A. (2003). Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358. (Pubitemid 36538359)
109. Tillisch, J., Brunken, R., Marshall, R., et al. (1986). Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N. Engl. J. Med. 314, 884-888. (Pubitemid 16126116)
110. Tio, R.A., Tan, E.S., Jessurun, G.A., et al. (2004). PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. J. Nucl. Med. 45, 1437-1443. (Pubitemid 47618496)
111. Uriel, S., Brey, E.M., and Greisler, H.P. (2006). Sustained low levels of fibroblast growth factor-1 promote persistent micro-vascular network formation. Am. J. Surg. 192, 604-609. (Pubitemid 44634338)
112. Vale, P.R., Losordo, D.W., Milliken, C.E., et al. (2000). Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102, 965-974. (Pubitemid 30656004)
113. Vassalli, G., Bueler, H., Dudler, J., et al. (2003). Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int. J. Cardiol. 90, 229-238. (Pubitemid 37087882)
114. Whitlock, P.R., Hackett, N.R., Leopold, P.L., et al. (2004). Ade-novirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther. 9, 67-75. (Pubitemid 38208329)
115. Witzenbichler, B., Asahara, T., Murohara, T., et al. (1998). Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153, 381-394. (Pubitemid 28373650)
116. World Health Organization (WHO). (2013). Media centre: Cardiovascular diseases (CVDs). Fact sheet N317, updated March 2013. www.who.int/mediacentre/ factsheets/fs317/en/(accessed October 2013).
117. Yang, Z.J., Zhang, Y.R., Chen, B., et al. (2009). Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol. Biol. Rep. 36, 1323-1329.
118. Ye, L., Haider, H.K., Jiang, S., et al. (2007a). Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies. Eur. J. Heart Fail. 9, 458-465. (Pubitemid 46562589)
119. Ye, L., Haider, H.K., Tan, R., et al. (2007b). Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 116, I113-I120. (Pubitemid 47480778)
120. Yuan, B., Zhao, Z., Zhang, Y.R., et al. (2008). Short-term safety and curative effect of recombinant adenovirus carrying he-patocyte growth factor gene on ischemic cardiac disease. In Vivo 22, 629-632.
121. Zachary, I., and Morgan, R.D. (2011). Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart 97, 181-189.